ReviewCurrent cardiology reports2026
Similarities and Differences Between the Extravascular and the Subcutaneous Implantable Cardioverter-Defibrillator: Clinical Selection and Implantation (Part 1).
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review examines the two non-transvenous implantable cardioverter-defibrillator (ICD) platforms; the subcutaneous ICD (S-ICD) and the extravascular ICD (EV-ICD), providing a framework for patient selection, preimplant screening, and implantation. RECENT
findingsLong-term trial and registry data confirm that the S-ICD provides reliable defibrillation without intravascular leads, with lower rates of lead failure, infection, and pneumothorax compared to transvenous systems. The EV-ICD, utilizing a substernal lead, has demonstrated effective defibrillation and anti-tachycardia pacing in approximately 77% of episodes, while offering pause-prevention pacing in a smaller pulse generator with greater projected longevity. Device selection should be individualized based on pacing requirements, prior sternotomy status, and anticipated arrhythmia substrate. The S-ICD remains the only option after sternotomy, while the EV-ICD extends the non-transvenous paradigm by integrating anti-tachycardia and pause-prevention pacing. Together, these devices offer complementary solutions for patients who do not require chronic pacing or resynchronization therapy.
Indexed as
Identifiers
42720711What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.